AZEDRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Azedra, and what generic alternatives are available?
Azedra is a drug marketed by Progenics Pharms Inc and is included in one NDA.
The generic ingredient in AZEDRA is iobenguane i-131. Additional details are available on the iobenguane i-131 profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZEDRA?
- What are the global sales for AZEDRA?
- What is Average Wholesale Price for AZEDRA?
Summary for AZEDRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 12 |
| Clinical Trials: | 3 |
| Patent Applications: | 340 |
| Drug Prices: | Drug price information for AZEDRA |
| What excipients (inactive ingredients) are in AZEDRA? | AZEDRA excipients list |
| DailyMed Link: | AZEDRA at DailyMed |
Recent Clinical Trials for AZEDRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| David Bushnell | Phase 1/Phase 2 |
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Progenics Pharmaceuticals, Inc. | Phase 1/Phase 2 |
US Patents and Regulatory Information for AZEDRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | AZEDRA | iobenguane i-131 | SOLUTION;INTRAVENOUS | 209607-001 | Jul 30, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
